Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Key facts
- Who runs it
- Abbott Medical Devices
- Where
- Albany, Ann Arbor, Asheville, Atlanta, Aurora, Austin, Balitmore, Baltimore, Bay Shore, Birmingham, Boise, Bradenton, Buffalo, Charleston, Charlotte, Charlottesville, Chicago, Cincinnati, Clearwater, Cleveland, Dallas, Delray Beach, Detroit, Falls Church, Fresno, Gainesville, Hackensack, Houston, Indianapolis, Kansas City, Little Rock, Los Angeles, Manchester, Marietta, Memphis, Miami, Milwaukee, Minneapolis, Missoula, Morgantown, Nashville, New Brunswick, New York, Newark, Oak Lawn, Phoenix, Pittsburgh, Portland, Rochester, Sacramento, San Diego, San Francisco, Scottsdale, Seattle, Silver Spring, Springfield, St Louis, Stanford, Tallahassee, Thousand Oaks, Tulsa, Weston, and Wichita, United StatesSee the 73 sitesAlso in 1 other country, 5 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 103 people enrolled
- Started
- 15 Jun 2018
- Expected to end
- Jun 2028
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tendyne Mitral Valve System
- MitraClip System
- Record updated
- 23 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 39 criteriaShow less
Who can take part
- Symptomatic, moderate-to-severe or severe mitral regurgitation (MR ≥ Grade III per American Society of Echocardiography criteria), or severe mitral annular calcification (MAC), where a transcatheter therapy is deemed more appropriate than open surgery by the local site heart team; Note: MR and MS severity must be determined by assessment of a qualifying transesophageal echocardiogram (TEE) and transthoracic echocardiogram (TTE), obtained within 120 days prior to subject consent, and must be confirmed by the Echocardiography Core Laboratory; Note: Patients with severe MAC must have symptomatic mitral valve disease associated with MR≥ Grade III, or severe mitral stenosis (MS), or both moderate MR and moderate MS as assessed by the Echocardiography Core Laboratory
- NYHA Functional Classification ≥ II (if Class IV, patient must be ambulatory)
- The local site heart team determines that the subject has been adequately treated per applicable standards for coronary artery disease (e.g., revascularization), left ventricular dysfunction (e.g., cardiac resynchronization therapy) and heart failure (e.g., GDMT). The SEC must concur that the subject has been adequately treated
- The local site heart team and the SEC concur on the intended study cohort for the subject; Randomized cohort: Eligibility for this cohort is limited to subjects where the local site heart team deems the mitral valve anatomy is suitable for TEER and are within approved Mitra Clip indications, which must be confirmed by experienced Mitra Clip operators within the SEC. Subjects with primary MR must be at prohibitive surgical risk, while subjects with secondary MR must be symptomatic despite maximally-tolerated guideline-directed medical therapy and meet the Mitra Clip Indications for Use; Non-repairable cohort: Eligibility for this cohort is limited to subjects where the local site heart team deems the mitral valve anatomy is not suitable for TEER with Mitra Clip or does not meet Mitra Clip indications, which must be confirmed by experienced Mitra Clip operators from the SEC; Severe MAC cohort: Eligibility for this cohort is limited to subjects where the local site heart team deems the degree of MAC renders the subject unsuitable for mitral valve surgery; Severe MAC CAP cohort: Eligibility for this cohort is identical to the original Severe MAC cohort
- Age 18 years or older at time of consent
- Subject has been informed of the nature of the trial and agrees to its provisions, including the possibility of randomization to the Control group, complying with trial required testing, medications, and follow-up visits, and has provided written informed consent
Who cannot take part
- Prior surgical or interventional treatment of mitral valve involving implantation of prosthetic material (e.g. valve repair or replacement, or Mitra Clip)
- Any surgical or interventional procedure within the period of 60 days prior to or planned procedure 60 days following subject registration
- Implant or revision of CRT device within 90 days prior to intended subject registration
- Myocardial infarction within 30 days prior to intended subject registration
- CVA within 6 months prior to intended subject registration
- Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure
- Subject has COPD requiring continuous home oxygen therapy or chronic outpatient oral steroid use
- Status 1 heart transplant or prior orthotopic heart transplantation
- Currently participating in an investigational drug or another device trial that has not reached its primary endpoint; Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials
- Chest condition that prevents transapical access
- Aortic valve disease requiring surgery or transcatheter intervention
- Tricuspid valve disease requiring surgery or transcatheter intervention
- Symptomatic, unresolved multi-vessel or unprotected left main coronary artery disease (e.g., active ischemia) requiring stenting or CABG
- Any of the following: leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy if cannot be adequately treated
- History of endocarditis within 6 months of planned implant procedure
- Active systemic infection requiring antibiotic therapy
- Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution, anti-coagulation or antiplatelet therapy) that cannot be adequately managed medically
- Known hypersensitivity to nickel or titanium
- Subject is undergoing hemodialysis due to chronic renal failure
- Subject has pulmonary arterial hypertension (fixed PAS >70mmHg). Note: If PAS > 70mmHg, site must provide documentation PAS is not fixed in order to be eligible
- Subjects with non-cardiac comorbidities that are likely to result in a life expectancy of less than 12 months
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
- LVEF less than 25% assessed by the site based on a TTE obtained within 120 days prior to subject consent; Note: LVEF will be principally based on TTE and confirmed by the Echocardiography Core Laboratory
- LVEDD > 7.0 cm assessed by the site based on a TTE obtained within 120 days prior to subject consent; Note: A qualifying LVEDD must be confirmed by the Echocardiography Core Laboratory
- Pregnant, lactating, or planning pregnancy during the clinical investigation follow-up period; Note: Female subjects of childbearing age should be instructed to use safe contraception (e.g. intrauterine devices, hormonal contraceptives: contraceptive pills, implants, transdermal patches hormonal vaginal devices, injections with prolonged release)
- Mitral valvular vegetation or mass
- Left Ventricle or Left Atrium thrombus
- Mitral pathoanatomy and LVOT anatomy deemed not suitable for Tendyne transcatheter mitral valve implantation
- Severe tricuspid regurgitation or severe right ventricular dysfunction
- Unresolved severe symptomatic carotid stenosis (> 70% by ultrasound)
- Hypertrophic or restrictive cardiomyopathy, or constrictive pericarditis
- Subjects in whom TEE is contraindicated or high risk
- Modified Rankin Scale ≥ 4 disability
Where in United States
Also in 1 other country, 5 sites
- Albany Medical College at Albany Medical CenterAlbany, United States
- University of Michigan Medical CenterAnn Arbor, United States
- Mission HealthAsheville, United States
- Emory University HospitalAtlanta, United States
- Piedmont Heart InstituteAtlanta, United States
- University of Colorado HospitalAurora, United States
- St. David's Healthcare Office of ResearchAustin, United States
- MedStar Union Memorial HospitalBalitmore, United States
- University of Maryland Medical CenterBaltimore, United States
- Northwell Health/South Shore University HospitalBay Shore, United States
- Baptist Medical Center PrincetonBirmingham, United States
- UAB University HospitalBirmingham, United States
- St. Alphonsus Regional Medical CenterBoise, United States
- Manatee Memorial HospitalBradenton, United States
- Buffalo General Medical CenterBuffalo, United States
- Medical University of South CarolinaCharleston, United States
- Atrium Health - Carolinas Medical CenterCharlotte, United States
- Novant Health Heart and Vascular Research InstituteCharlotte, United States
- University of Virginia Medical CenterCharlottesville, United States
- Rush University Medical CenterChicago, United States
- University of Cincinnati Medical CenterCincinnati, United States
- BayCare Healthcare System - Morton Plant HospitalClearwater, United States
- The Cleveland Clinic FoundationCleveland, United States
- Baylor Scott & White The Heart Hospital - DallasDallas, United States
- Medical City Dallas HospitalDallas, United States
- Delray Medical CenterDelray Beach, United States
- Henry Ford HealthDetroit, United States
- Inova Fairfax HospitalFalls Church, United States
- Fresno Heart HospitalFresno, United States
- HCA Florida north florida HospitalGainesville, United States
- University of FloridaGainesville, United States
- Hackensack University Medical CenterHackensack, United States
- UTHealth Memorial HermannHouston, United States
- Ascension St. VincentIndianapolis, United States
- Saint Luke's Hospital of Kansas CityKansas City, United States
- Baptist Health Medical CenterLittle Rock, United States
- Cedars-Sinai Medical CenterLos Angeles, United States
- University of Southern California University HospitalLos Angeles, United States
- Catholic Medical CenterManchester, United States
- Wellstar Kennestone Regional Medical CenterMarietta, United States
- Baptist Memorial HospitalMemphis, United States
- Baptist Hospital of MiamiMiami, United States
- Medical College of WisconsinMilwaukee, United States
- Abbott-Northwestern HospitalMinneapolis, United States
- The International Heart Institute of MontanaMissoula, United States
- West Virginia UniversityMorgantown, United States
- Ascension Saint ThomasNashville, United States
- TriStar Centennial Medical centerNashville, United States
- Robert Wood Johnson University HospitalNew Brunswick, United States
- Lenox Hill HospitalNew York, United States
- New York Presbyterian Hospital/Cornell UniversityNew York, United States
- Newark Beth Israel Medical CenterNewark, United States
- Advocate Christ Medical CenterOak Lawn, United States
- Banner University Medical CenterPhoenix, United States
- Allegheny General Hospital - ASRIPittsburgh, United States
- UPMC ShadysidePittsburgh, United States
- Providence Heart & Vascular InstitutePortland, United States
- Mayo ClinicRochester, United States
- Sutter Medical Center SacramentoSacramento, United States
- University of California, Davis Medical CenterSacramento, United States
- San Diego Cardiac CenterSan Diego, United States
- University of California at San FranciscoSan Francisco, United States
- Scottsdale Healthcare - SheaScottsdale, United States
- Swedish Medical Center - Heart & VascularSeattle, United States
- Adventist HealthCare White Oak Medical CenterSilver Spring, United States
- Prairie Education & Research CooperativeSpringfield, United States
- St. Louis University HospitalSt Louis, United States
- Stanford Health CareStanford, United States
- Tallahassee Research InstituteTallahassee, United States
- Los Robles Regional Medical CenterThousand Oaks, United States
- Oklahoma Heart Institute at UticaTulsa, United States
- Cleveland Clinic FloridaWeston, United States
- Ascension Via Christi Hospitals WichitaWichita, United States
About the trial
What the trial wants to find out
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Plan (MAC CAP). Subjects in the Randomized cohort were randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts were receive the trial device.
Read full original descriptionShow less
The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) was to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification.
This randomized controlled trial would provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System would be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who were not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and were also not suitable for transcatheter repair with MitraClip, would be enrolled in the Non-repairable cohort.
Subjects would be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.
The 5 groups in the trial
- Randomized Cohort - Treatment GroupTreatment being tested
Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
Treatment: Tendyne Mitral Valve System
- Randomized Cohort - Control GroupExisting treatment, for comparison
Treatment of mitral regurgitation within commercially approved MitraClip system indications
Treatment: MitraClip System
- Non-repairable CohortTreatment being tested
Treatment of mitral regurgitation with the Tendyne Transcatheter Mitral Valve System
Treatment: Tendyne Mitral Valve System
- Severe Mitral Annular Calcification (MAC) CohortTreatment being tested
Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System
Treatment: Tendyne Mitral Valve System
- Severe Mitral Annular Calcification Continued Access Plan (MAC CAP) CohortTreatment being tested
Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Transcatheter Mitral Valve System after the completion of enrollment in the Severe MAC Cohort
Treatment: Tendyne Mitral Valve System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 23 July 2026